Literature DB >> 7709417

Interleukin-1 as a pathogenetic mediator of ischemic brain damage in rats.

Y Yamasaki1, N Matsuura, H Shozuhara, H Onodera, Y Itoyama, K Kogure.   

Abstract

BACKGROUND AND
PURPOSE: It has been suggested that interleukin-1 (IL-1) is a potent inflammatory mediator and that it is synthesized and secreted into the brain parenchyma. The aim of the present study is to evaluate the contribution of IL-1 to brain edema formation after focal brain ischemia.
METHODS: The brain water content was measured to evaluate postischemic brain injury in rats after 60 minutes of middle cerebral artery occlusion and reperfusion. The effects of exogenous application of recombinant human interleukin-1 beta (rhIL-1 beta), anti-interleukin-1 beta neutralizing antibodies (anti-IL-1 beta), and the IL-1 blocker zinc protoporphyrin (ZnPP) on brain water content were observed, and histological technique was used to measure the infarction size and number of inflammatory cells infiltrated into the brain.
RESULTS: Transient ischemia induced marked increase of brain water content, necrosis, and neutrophilic infiltration in the cortex perfused by the middle cerebral artery and the dorsal and ventral areas of the caudate putamen. Injection of rhIL-1 beta into the left lateral ventricle immediately after reperfusion markedly enhanced ischemic brain edema formation in these three areas in a dose-dependent manner (88.4 +/- 0.7% and 86.6 +/- 0.4% in the dorsal and ventral parts of the caudate putamen, respectively, in rats treated with 10 ng rhIL-1 beta; P < .01). rhIL-1 beta also increased the size of the brain infarction, and it tended to increase the number of infiltrating neutrophils in ischemic areas and the number of neutrophils adherent to the endothelium. In contrast, administration of anti-IL-1 beta and ZnPP into the left cerebral ventricle attenuated the postischemic increase of brain water content and decreased the size of brain infarction (83.5 +/- 2.0% and 79.9 +/- 2.0% in the dorsal and ventral parts of the caudate putamen, respectively, in rats treated with 10 micrograms anti-IL-1 beta; P < .01). The number of neutrophils that infiltrated into ischemic areas also tended to decrease with anti-IL-1 beta or ZnPP treatment.
CONCLUSIONS: Application of rhIL-1 beta augmented the increase of brain water content, and application of anti-IL-1 beta depressed the increase of water content. These results tended to correlate with the neutrophilic infiltration into the parenchyma. It thus appears that IL-1 beta may play an important role in ischemic brain damage after reperfusion.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7709417     DOI: 10.1161/01.str.26.4.676

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  134 in total

1.  Interleukin-1β-induced barrier dysfunction is signaled through PKC-θ in human brain microvascular endothelium.

Authors:  Robert R Rigor; Richard S Beard; Olesya P Litovka; Sarah Y Yuan
Journal:  Am J Physiol Cell Physiol       Date:  2012-03-07       Impact factor: 4.249

2.  MicroRNA-130a represses transcriptional activity of aquaporin 4 M1 promoter.

Authors:  Sugunavathi Sepramaniam; Lim Kai Ying; Arunmozhiarasi Armugam; E M Wintour; Kandiah Jeyaseelan
Journal:  J Biol Chem       Date:  2012-02-13       Impact factor: 5.157

Review 3.  Gender differences in neurological disease: role of estrogens and cytokines.

Authors:  Anna Członkowska; Agnieszka Ciesielska; Grazyna Gromadzka; Iwona Kurkowska-Jastrzebska
Journal:  Endocrine       Date:  2006-04       Impact factor: 3.633

Review 4.  The inflammatory response in stroke.

Authors:  Qing Wang; Xian Nan Tang; Midori A Yenari
Journal:  J Neuroimmunol       Date:  2006-12-26       Impact factor: 3.478

Review 5.  Inflammatory responses in brain ischemia.

Authors:  Masahito Kawabori; Midori A Yenari
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

6.  Delayed administration of interleukin-1 receptor antagonist protects against transient cerebral ischaemia in the rat.

Authors:  Nicholas J Mulcahy; Jerard Ross; Nancy J Rothwell; Sarah A Loddick
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

7.  Non-muscle Mlck is required for β-catenin- and FoxO1-dependent downregulation of Cldn5 in IL-1β-mediated barrier dysfunction in brain endothelial cells.

Authors:  Richard S Beard; Ricci J Haines; Kevin Y Wu; Jason J Reynolds; Stephanie M Davis; John E Elliott; Nikolay L Malinin; Victor Chatterjee; Byeong J Cha; Mack H Wu; Sarah Y Yuan
Journal:  J Cell Sci       Date:  2014-02-12       Impact factor: 5.285

8.  Interleukin-1β enhances neuronal vulnerability to proNGF-mediated apoptosis by increasing surface expression of p75(NTR) and sortillin.

Authors:  S Choi; W J Friedman
Journal:  Neuroscience       Date:  2013-11-06       Impact factor: 3.590

9.  Plasma interleukin-1beta concentration is associated with stroke in sickle cell disease.

Authors:  Kwaku Asare; Beatrice E Gee; Jonathan K Stiles; Nana O Wilson; Adel Driss; Alexander Quarshie; Robert J Adams; Abdullah Kutlar; Jacqueline M Hibbert
Journal:  Cytokine       Date:  2009-11-08       Impact factor: 3.861

Review 10.  The expanding interleukin-1 family and its receptors: do alternative IL-1 receptor/signaling pathways exist in the brain?

Authors:  Herve Boutin; Ian Kimber; Nancy J Rothwell; Emmanuel Pinteaux
Journal:  Mol Neurobiol       Date:  2003-06       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.